N-(3-((5-Cyclopropyl-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)propyl)cyclobutanecarboxamide

Catalog No. :
ACKCZO282
CAS No. :
1190379-24-8
Molecular Formula :
C19H27N7O
Molecular Weight :
369.47

IUPAC Name:N-(3-((5-cyclopropyl-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)propyl)cyclobutanecarboxamide

N-(3-((5-Cyclopropyl-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)propyl)cyclobutanecarboxamide structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NameN-(3-((5-Cyclopropyl-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)propyl)cyclobutanecarboxamide
IUPAC NameN-(3-((5-cyclopropyl-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)propyl)cyclobutanecarboxamide
Molecular FormulaC19H27N7O
Molecular Weight369.47
SMILESO=C(C1CCC1)NCCCNC2=NC(NC3=CN(C)N=C3)=NC=C2C4CC4
InChI KeyYOFJPZPGHXWQJB-UHFFFAOYSA-N
SynonymN-[3-({5-Cyclopropyl-2-[(1-methyl-1H-pyrazol-4-yl)amino]-4-pyrimidinyl}amino)propyl]cyclobutanecarboxamide;MRT-68771;Cyclobutanecarboxamide, N-[3-[[5-cyclopropyl-2-[(1-methyl-1H-pyrazol-4-yl)amino]-4-pyrimidinyl]amino]propyl]-
CAS No.1190379-24-8

Synthetic Route by SureRoute

1. ACKCZO282 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACNUTW093 route compound structure diagram
    ACNUTW0935006-22-4 In Stock
  4. Then
  5. ACKCZO282 route product structure diagram
    ACKCZO2821190379-24-8
Inquiry

2. ACKCZO282 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACHNKZ705 route compound structure diagram
    ACHNKZ7051063734-49-5 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACKCZO282 route product structure diagram
    ACKCZO2821190379-24-8
Inquiry

Comments (0)